Related Experiment Videos
Rotavirus vaccine and intussusception. Where do we go from here?
1Division of Pediatric Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island. pdennehy@lifespan.org
Infectious Disease Clinics of North America
|April 17, 2001
Summary
Rotavirus vaccine development evolved from animal strains to reassortment vaccines. Early vaccines showed an increased risk of intussusception, a serious condition, necessitating further research.
Area of Science:
- Virology
- Vaccinology
- Pediatric Gastroenterology
Background:
- Rotavirus was discovered in 1973, prompting vaccine development efforts.
- Vaccine technology advanced from monovalent attenuated animal strains to multivalent human-animal reassortment vaccines.
- The first rotavirus vaccine, a rhesus-human tetravalent formulation, was licensed in 1998.
Purpose of the Study:
- To review the evolution of rotavirus vaccine technology.
- To highlight the safety concerns associated with early rotavirus vaccines.
- To emphasize the need for understanding the intussusception risk.
Main Methods:
- Literature review of rotavirus vaccine development and safety data.
- Analysis of historical vaccine licensing and withdrawal information.
- Synthesis of current understanding regarding rotavirus and intussusception.
Main Results:
- Rotavirus vaccine technology has progressed significantly since its discovery.
- The first licensed rotavirus vaccine was withdrawn due to an association with intussusception.
- The underlying reasons for the increased intussusception risk remain undiscovered.
Conclusions:
- The future of rotavirus vaccine development hinges on elucidating the cause of the intussusception risk.
- Further research is critical to ensure the safety and efficacy of future rotavirus vaccines.
- Understanding this association is key to preventing severe outcomes in infants.